Background/Aims: The activation of proteinase-activated receptors (PARs) has been implicated in the development of important hallmarks of inflammation, including in vivo leukocyte recruitment. Here, we examined the effects of aprotinin, a potent inhibitor of trypsin proteinase and the kallikrein-kinin system, and the PAR-4 antagonist YPGKF-NH2 (tcY-NH2) on neutrophil recruitment in response to carrageenan and trypsin in the pleural cavity of mice. Methods: BALB/c mice were intrapleurally injected with trypsin or PAR-4-activating peptide AY-NH2, pretreated with aprotinin or tcY-NH2 (1 µg/cavity) prior to an intrapleural injection of trypsin or carrageenan, or pretreated with leukotriene B4 antagonist U-75302 (3 µg/cavity) prior to a trypsin injection. The number of infiltrating neutrophils was evaluated after 4 h. Results: PAR-4-activating peptide AY-NH2 and trypsin-induced neutrophil recruitment was inhibited by aprotinin, tcY-NH2 or U-75302. Aprotinin and tcY-NH2 also inhibited neutrophil recruitment induced by carrageenan. Conclusion: These data suggest a key role for PAR-4 in mediating neutrophil recruitment in a mouse model of pleurisy induced by the activity of trypsin or trypsin-like enzymes.

Keywords:
Proteinase-activated receptor-4, Neutrophils, Neutrophils recruitment, Pleurisy
1.
Faurschou M, Borregaard N: Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 2003;5:1317–1327.
2.
Korkmaz B, Horwitz MS, Jenne DE, Gauthier F: Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 2010;62:726–759.
3.
Kobayashi SD, DeLeo FR: Role of neutrophils in innate immunity: a systems biology-level approach. Wiley Interdiscip Rev Syst Biol Med 2009;1:309–333.
4.
Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 1989;320:365–376.
5.
Kobayashi Y: The role of chemokines in neutrophil biology. Front Biosci 2008;13:2400–2407.
6.
Samuelsson B: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568–575.
7.
Hollenberg MD, Compton SJ: International Union of Pharmacology XXVIII. Proteinase-activated receptors. Pharmacol Rev 2002;54:203–217.
8.
Coughlin SR: Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005;3:1800–1814.
9.
Vergnolle N, Derian CK, D’Andrea MR, Steinhoff M, Andrade-Gordon P: Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol 2002;169:1467–1473.
10.
Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, Thompson PJ, Stewart GA: Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 2002;168:3577–3585.
11.
Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD: Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005;26:1–43.
12.
Martin L, Augé C, Boué J, Buresi MC, Chapman K, Asfaha S, Andrade-Gordon P, Steinhoff M, Cenac N, Dietrich G, Vergnolle N: Thrombin receptor: an endogenous inhibitor of inflammatory pain, activating opioid pathways. Pain 2009;146:121–129.
13.
Vergnolle N: Protease-activated receptors as drug targets in inflammation and pain. Pharmacol Ther 2009;123:292–309.
14.
Ramachandran R, Hollenberg MD: Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 2008;153(suppl 1):S263–S282.
15.
Cottrell GS, Amadesi S, Grady EF, Bunnett NW: Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 2004;279:13532–13539.
16.
Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, Diamandis EP, Hollenberg MD: Proteinase-activated receptors (PARs), targets for kallikrein signalling. J Biol Chem 2006;281:32095–32112.
17.
Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR: Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000;275:6819–6823.
18.
Kataoka H, Hamilton JR, McKemy DD, Camerer E, Zheng YW, Cheng A, Griffin C, Coughlin SR: Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 2003;102:3224–3231.
19.
McDougall JJ, Zhang C, Cellars L, Joubert E, Dixon CM, Vergnolle N: Triggering of proteinase-activated receptor 4 leads to joint pain and inflammation in mice. Arthritis Rheum 2009;60:728–737.
20.
Houle S, Papez MD, Ferazzini M, Hollenberg MD, Vergnolle N: Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br J Pharmacol 2005;146:670–678.
21.
Slofstra SH, Bijlsma MF, Groot AP, Reitsma PH, Lindhout T, ten Cate H, Spek CA: Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood 2007;110:3176–3182.
22.
Braga AD, Miranda JP, Ferreira GM, Bilheiro RP, Duarte ID, Francischi JN, Klein A: Blockade of proteinase-activated receptor-4 inhibits the eosinophil recruitment induced by eotaxin-1 in the pleural cavity of mice. Pharmacology 2010;86:224–230.
23.
Smith M, Kocher HM, Hunt BJ: Aprotinin in severe acute pancreatitis. Int J Clin Pract 2010;64:84–92.
24.
Falcone RC, Aharony D: Modulation of ligand binding to leukotriene B4 receptors on guinea pig lung membranes by sulfhydryl modifying reagents. J Pharmacol Exp Ther 1990;255:565–571.
25.
Richards IM, Griffin RL, Oostveen JA, Morris J, Wishka DG, Dunn CJ: Effect of the selective leukotriene B4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophilia in sensitized guinea pigs. Am Rev Respir Dis 1989;140:1712–1716.
26.
Das AM, Flower RJ, Hellewell PG, Teixeira MM, Perretti M: A novel murine model of allergic inflammation to study the effect of dexamethasone on eosinophil recruitment. Br J Pharmacol 1997;121:97–104.
27.
Klein A, Talvani A, Silva PM, Martins MA, Wells TN, Proudfoot A, Luckacs NW, Teixeira MM: Stem cell factor-induced leukotriene B4 production cooperates with eotaxin to mediate the recruitment of eosinophils during allergic pleurisy in mice. J Immunol 2001;167:524–531.
28.
Mathieu J, Tissot M, Nolibe D, Florentin I, Kergonou JF, Giroud JP: Local and systemic effects of an acute inflammation on eicosanoid generation capacity of polymorphonuclear cells and macrophages. Int J Exp Pathol 1990;71:603–616.
29.
Chen D, Carpenter A, Abrahams J, Chambers RC, Lechler RI, McVey JH, Dorling AJ: Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med 2008;205:1739–1746.
30.
Su X, Camerer E, Hamilton JR, Coughlin SR, Matthay MA: Protease-activated receptor-2 activation induces acute lung inflammation by neuropeptide-dependent mechanisms. J Immunol 2005;175:2598–2605.
31.
Vergnolle N: Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo. J Immunol 1999;163:5064–5069.
32.
Bolton SJ, McNulty CA, Thomas RJ, Hewitt CR, Wardlaw AJ: Expression of and functional responses to proteinase-activated receptors on human eosinophils. J Leukoc Biol 2003;74:60–68.
33.
Paszcuk AF, Quintão NL, Fernandes ES, Juliano L, Chapman K, Andrade-Gordon P, Campos MM, Vergnolle N, Calixto JB: Mechanisms underlying the nociceptive and inflammatory responses induced by trypsin in the mouse paw. Eur J Pharmacol 2008;581:204–215.
34.
Saleh TS, Calixto JB, Medeiros YS: Effects of antiinflammatory drugs upon nitrate and myeloperoxidase levels in the mouse pleurisy induced by carrageenan. Peptides 1999;20:949–956.
35.
Okuno T, Yokomizo T, Hori T, Miyano M, Shimizu T: Leukotriene B4 receptor and the function of its helix 8. J Biol Chem 2005;280:32049–32052.
36.
Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T: A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997;387:620–624.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.